Medtronic Hired Executive to Scale Cardiac Ablation Unit
The appointment of Felicia Kurz signals a focus on commercial growth for the company's electrophysiology portfolio.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you trust that executive leadership changes at major medical companies improve healthcare outcomes?
Medtronic has appointed Felicia Kurz as the new Vice President of Cardiac Ablation Solutions. The move comes as the company seeks to scale its electrophysiology business following recent regulatory expansions for its medical technology platforms.
Why it matters
Medtronic is prioritizing leadership depth in commercial strategy to compete more effectively within the specialized electrophysiology sector. This shift focuses on accelerating market penetration for its core ablation technologies.
Felicia Kurz brings 10 years of experience from Siemens Healthineers to her new leadership role, including 3 years served as SVP of Advanced Therapies for North America. Her appointment follows the recent EU regulatory approval for the Medtronic Affera platform.
The players
Medtronic
A global leader in medical technology with its corporate headquarters based in Minnesota.
Felicia Kurz
The new Vice President of Cardiac Ablation Solutions who previously served as Senior Vice President of Advanced Therapies for North America at Siemens Healthineers.
Rebecca Seidel
A leadership figure at Medtronic who announced the new executive appointment.
Siemens Healthineers
A large-scale international medical device company that serves as a competitor to Medtronic in various clinical imaging and therapy markets.
The details
Kurz will oversee the commercial strategy for cardiac ablation solutions, an area Medtronic is actively investing in to drive growth. The company is currently scaling its Affera Sphere-9 pulsed-field ablation catheter, which recently secured an expanded indication for ventricular tachycardia and premature ventricular complexes. This strategic hire aims to leverage her previous experience in managing advanced therapy teams to strengthen Medtronic's market position.
Timeline
September 2026: Affera system received expanded EU indication.
October 5, 2026: Rebecca Seidel announced the hiring of Felicia Kurz via LinkedIn.
Market Landscape
The expansion of the Affera system's clinical indications follows the established compliance pathways set by the European Union's Medical Device Regulation (MDR) certification processes. This development highlights the standard industry focus on navigating regulatory approvals to drive product portfolio growth.
Operators in the medical device sector should monitor how Medtronic's expanded clinical indications influence pricing and hospital adoption rates for ablation systems. The entry of new leadership often signals shifts in regional channel strategy and procurement requirements for specialty clinics.
The takeaway
Medtronic's appointment underscores the importance of scaling commercial expertise to support newly approved medical technology platforms. Operators should keep track of how these updated regulatory indications impact regional supply chains and clinical adoption metrics in the coming year.
Further reading
For more on industry shifts in medical devices, visit the Healthcare section.
Source note: This article includes information reported by MassDevice.
Live Poll
Do you trust that executive leadership changes at major medical companies improve healthcare outcomes?
